{"filing":{"accession_number":"0001672688-26-000118","cik":"0001672688","ticker":"ABSI","company_name":"Absci Corp","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"absc-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/absc-20260624.htm"},"events":[{"id":13349,"run_id":11856,"accession_number":"0001672688-26-000118","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, a novel antibody candidate. The disclosure highlights favorable safety findings, pharmacokinetic profile (estimated half-life of at least 65 days), and advancement to the multiple ascending dose phase. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical trial milestone—making operational_other the most appropriate classification.","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10464,"accession_number":"0001672688-26-000118","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, a novel antibody candidate. The disclosure highlights favorable safety findings, pharmacokinetic profile (estimated half-life of at least 65 days), and advancement to the multiple ascending dose phase. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical trial milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:32:38.438963+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10464,"accession_number":"0001672688-26-000118","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, a novel antibody candidate. The disclosure highlights favorable safety findings, pharmacokinetic profile (estimated half-life of at least 65 days), and advancement to the multiple ascending dose phase. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical trial milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:32:38.438963+00:00","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-06-24"}]}